Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 2 recruiting now later-stage tilt small index

Nasolacrimal Duct Obstruction: later-stage trial registry

2 of 3 indexed Nasolacrimal Duct Obstruction trials are currently recruiting, with more weight in Phase 3-4.

Corpus placement: #5,209 of 28,707 conditions by registered trial count.

3 US clinical trials · 2 currently recruiting · #5,209 of 28,707 conditions by registered trial count

Nasolacrimal Duct Obstruction: 3 US clinical trials tracked, 2 recruiting.

Nasolacrimal Duct Obstruction is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is University of Arkansas, running 1 of these trials.

Enrollment posture brief

Registry condition nasolacrimal-duct-obstruction

OPEN 2 | RECR 67% | LATE 2 | EARLY 0 | RANK #5209 | SPON 1

Nearest open-share peer: Acute Hypoxemic Respiratory Failure (67% recruiting · 6 trials)

Ablation80%ACL Reconstruction80%Nasolacrimal Duct Obstru (this)Nasolacrimal Duct Obstru (th…67%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near Nasolacrimal Duct Obstruction

Nasolacrimal Duct Obstruction lists 2 open slots (67% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Nasolacrimal Duct Obstruction on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Nasolacrimal Duct Obstruction is recruiting above its size-band peers.

    2 of 3 indexed trials (66.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 32

Phase Distribution

PhaseTrial count
Phase 3 2

Named interventions

Most-linked intervention names on Nasolacrimal Duct Obstruction records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Deferred Facility Probing Procedure
1 trials
Immediate Office Probing Procedure
1 trials
Modified Portable Endoscopic Camera Device
1 trials
Artificial Tears Methylcellulose Drug
1 trials

US sites by state

Facility locations filed on Nasolacrimal Duct Obstruction trials. A trial with sites in several states counts in each.

Tennessee 1 trials
Idaho 1 trials
Arkansas 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Nasolacrimal Duct Obstruction page

3 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 2 Nasolacrimal Duct Obstruction trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • University of Arkansas sponsors the most Nasolacrimal Duct Obstruction trials on record, review their full trial history before evaluating a specific study. See University of Arkansas's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Nasolacrimal Duct Obstruction condition card totals 3 registered trials; most-linked intervention Deferred Facility Probing; top US site state Tennessee. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.